Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GILD, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 10 uncommon options trades for Gilead Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 60% bullish and 40%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $258,167, and 5 are calls, for a total amount of $348,257.
What's The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $95.0 to $97.5 for Gilead Sciences over the last 3 months.
Volume & Open Interest Trends
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Gilead Sciences's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Gilead Sciences's whale activity within a strike price range from $95.0 to $97.5 in the last 30 days.
Gilead Sciences Call and Put Volume: 30-Day Overview
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | CALL | SWEEP | BEARISH | 02/21/25 | $3.2 | $3.05 | $3.05 | $95.00 | $152.5K | 5.3K | 1.0K |
| GILD | PUT | SWEEP | BULLISH | 09/19/25 | $7.9 | $7.85 | $7.85 | $97.50 | $124.0K | 11 | 261 |
| GILD | CALL | SWEEP | BULLISH | 06/20/25 | $5.15 | $5.0 | $5.05 | $97.50 | $83.3K | 664 | 166 |
| GILD | CALL | SWEEP | BULLISH | 01/31/25 | $0.73 | $0.72 | $0.73 | $96.00 | $53.5K | 561 | 784 |
| GILD | PUT | TRADE | BULLISH | 01/16/26 | $9.55 | $9.4 | $9.4 | $97.50 | $46.0K | 10 | 0 |
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Where Is Gilead Sciences Standing Right Now?
- With a volume of 2,022,026, the price of GILD is up 2.05% at $95.77.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 13 days.
What Analysts Are Saying About Gilead Sciences
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $114.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * In a positive move, an analyst from Morgan Stanley has upgraded their rating to Overweight and adjusted the price target to $113. * Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Gilead Sciences with a target price of $115.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Gilead Sciences, Benzinga Pro gives you real-time options trades alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
